Current Edition

chemistry manufacturing and control

Manufacturing issues force delay for PolarityTE’s skin repair hopeful

Manufacturing issues are common with regenerative medicines. And so it goes for PolarityTE’s investigational new drug submission for SkinTE. On Tuesday the Salt Lake Salt …

Continue Reading →

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug …

Continue Reading →

Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer

Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing cancer treatment drugs, announces today that its most advanced compound, GNS561, has received approval …

Continue Reading →